Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine

Shi, Rong; Xu, Zhangyao; Xu, Xining; Jin, Jingyi; Zhao, Yining; Wang, Tianming; Li, Yuanyuan

doi:10.1016/j.ejps.2018.11.010

Cited by 21 publications

(10 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The doses of metformin (100 mg/kg) and atorvastatin (20 mg/kg) used in our study were selected based on available literature [27,28,32] and did not cause any adverse effects in healthy rats. A dose of atorvastatin of 20 mg/kg may cause liver injury in diabetic rats [27] but is safe for healthy rats [32].…”

Section: Discussionmentioning

confidence: 99%

“…[27]; Tulip ® , batch number JK9440, Sequoia Capital, Menlo Park, California, USA), and metformin (100 mg/kg b.w. [28]; Metformax ® , batch number 16518316, Teva Pharmaceutical Industries Ltd., Petach Tikwa, Izrael) were administrated directly into the stomachs of live animals using a gastric probe (1 mL of each solution). A 10% dimethyl sulfoxide (DMSO) stock for sorafenib tosylate and 0.9% sodium chloride for atoravastatin and metformin were used to prepare the drug solutions.…”

Section: Animal Experimentsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats

et al. 2020

View full text Add to dashboard Cite

The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type 2 diabetes mellitus (T2DM) may often coexist. Protein transporters like organic cation (OCT) and multidrug and toxin extrusion (MATE) are involved in the response to sorafenib, as well as in that to the anti-diabetic drug metformin or atorvastatin, used in hyperlipidemia. Changes in the activity of these transporters may lead to pharmacokinetic interactions, which are of clinical significance. The study aimed to assess the sorafenib−metformin and sorafenib−atorvastatin interactions in rats. The rats were divided into five groups (eight animals in each) that received sorafenib and atorvastatin (ISOR+AT), sorafenib and metformin (IISOR+MET), sorafenib (IIISOR), atorvastatin (IVAT), and metformin (VMET). Atorvastatin significantly increased the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve (AUC) of sorafenib by 134.4% (p < 0.0001) and 66.6% (p < 0.0001), respectively. Sorafenib, in turn, caused a significant increase in the AUC of atorvastatin by 94.0% (p = 0.0038) and its metabolites 2−hydroxy atorvastatin (p = 0.0239) and 4−hydroxy atorvastatin (p = 0.0002) by 55.3% and 209.4%, respectively. Metformin significantly decreased the AUC of sorafenib (p = 0.0065). The AUC ratio (IISOR+MET group/IIISOR group) for sorafenib was equal to 0.6. Sorafenib did not statistically significantly influence the exposure to metformin. The pharmacokinetic interactions observed in this study may be of clinical relevance in HCC patients with coexistent hyperlipidemia or T2DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Animal Experimentsmentioning

confidence: 99%

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The interaction between metformin and berberine in their bioavailability is somehow contradictory. Shi et al [78] showed that berberine could decrease the C max , AUC from 0 to 4 h (AUC 0-4h ), and urinary and bile excretion, and increased the kidney tissue concentration of metformin in rats. On the other hand, coadministration of metformin increased the C max and AUC 0-4h of berberine with no significant difference in pharmacokinetics parameters between coadministration and berberine-only groups.…”

Section: From Drug Combination To Structural Linkage With Other Bioacmentioning

confidence: 99%

“…On the other hand, coadministration of metformin increased the C max and AUC 0-4h of berberine with no significant difference in pharmacokinetics parameters between coadministration and berberine-only groups. Metformin has also been shown to increase the kidney and liver concentrations and reduced the urinary and biliary excretion of berberine [78].…”

Section: From Drug Combination To Structural Linkage With Other Bioacmentioning

confidence: 99%

The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches

Habtemariam

2020

Biomedicines

View full text Add to dashboard Cite

Berberine is a quaternary isoquinoline alkaloid that has been isolated from numerous plants which are still in use today as medicine and herbal supplements. The great deal of enthusiasm for intense research on berberine to date is based on its diverse pharmacological effects via action on multiple biological targets. Its poor bioavailability resulting from low intestinal absorption coupled with its efflux by the action of P-glycoprotein is, however, the major limitation. In this communication, the chemical approach of improving berberine’s bioavailability and pharmacological efficacy is scrutinised with specific reference to type-2 diabetes and associated diseases such as hyperlipidaemia and obesity. The application of modern delivery systems, research from combination studies to preparation of berberine structural hybrids with known biologically active compounds (antidiabetic, antihyperlipidaemic and antioxidant), as well as synthesis approaches of berberine derivative are presented. Improvement of bioavailability and efficacy through in vitro and ex vivo transport studies, as well as animal models of bioavailability/efficacy in lipid metabolism and diabetes targets are discussed.

show abstract

“…Peficitinib, a pan-Janus kinase inhibitor, is used to treat rheumatoid arthritis ( Takeuchi et al, 2016 ). Peficitinib has been shown to inhibit the uptake of metformin in hOCT1-overexpressing cells ( Shibata et al, 2020 ). However, in clinical studies, the AUC, C max and CL R of metformin were only slightly reduced by peficitinib treatment in healthy male subjects.…”

Section: Interaction Of Organic Cation Transporter 1 With Clinical mentioning

confidence: 99%

Drug-Drug Interactions at Organic Cation Transporter 1

2021

View full text Add to dashboard Cite

The interaction between drugs and various transporters is one of the decisive factors that affect the pharmacokinetics and pharmacodynamics of drugs. The organic cation transporter 1 (OCT1) is a member of the Solute Carrier 22A (SLC22A) family that plays a vital role in the membrane transport of organic cations including endogenous substances and xenobiotics. This article mainly discusses the drug-drug interactions (DDIs) mediated by OCT1 and their clinical significance.

show abstract

Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine

Cited by 21 publications

References 40 publications

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats

The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches

Drug-Drug Interactions at Organic Cation Transporter 1

Contact Info

Product

Resources

About